Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 3:45 pm ET. The event will be accessible via webcast on Theravance.com in the Investors section.

Theravance Biopharma focuses on delivering innovative medicines, notably the FDA-approved YUPELRI (revefenacin) inhalation solution for chronic obstructive pulmonary disease (COPD). Additionally, the company is developing Ampreloxetine, a potential first-in-class norepinephrine reuptake inhibitor aimed at treating neurogenic orthostatic hypotension.

For further details about the conference and the company’s developments, visit www.theravance.com.

DUBLIN, April 10, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 22^nd Annual Needham Virtual Healthcare Conference on Monday, April 17 at 3:45 pm ET (12:45 pm PT/8:45 pm IST).

Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension, has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in multiple symptom atrophy patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-301792988.html

SOURCE Theravance Biopharma, Inc.

FAQ

When will Theravance Biopharma present at the Needham Virtual Healthcare Conference?

Theravance Biopharma will present on April 17, 2023, at 3:45 pm ET.

How can I access the webcast for the Theravance Biopharma conference?

The webcast can be accessed by visiting Theravance.com under the Investors section.

What is Theravance Biopharma known for?

Theravance Biopharma is known for developing YUPELRI, an inhalation solution for COPD, and Ampreloxetine for neurogenic orthostatic hypotension.

What time does the Needham Virtual Healthcare Conference presentation start?

The presentation starts at 3:45 pm ET (12:45 pm PT / 8:45 pm IST).

Where can I find more information about Theravance Biopharma?

More information can be found on their official website at www.theravance.com.